Product Details

Uniprot No.

Target Names

Alternative Names

CRL 2 antibody; CRL2 antibody; CRLF 2 antibody; Crlf2 antibody; CRLF2_HUMAN antibody; CRLF2Y antibody; Cytokine receptor CRL2 precusor antibody; Cytokine receptor like 2 antibody; Cytokine receptor like factor 2 antibody; Cytokine receptor like factor 2 precursor antibody; Cytokine receptor-like 2 antibody; Cytokine receptor-like factor 2 antibody; IL XR antibody; IL-XR antibody; ILXR antibody; Thymic stromal derived lymphopoietin receptor antibody; Thymic stromal lymphopoietin protein receptor antibody; Thymic stromal lymphopoietin receptor antibody; TSLP receptor antibody; TSLPR antibody

Species Reactivity

Human, Macaca fascicularis

Immunogen

Recombinant Human CRLF2 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

10A4

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA, WB

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000
WB	1:1000-1:5000

Protocols

ELISA Protocol
Western Blotting(WB) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

CRLF2, also known as thymic stromal lymphopoietin receptor (TSLPR), plays a central role in immune regulation by partnering with IL-7 receptor alpha to form the functional TSLP receptor complex. This signaling pathway influences dendritic cell activation, T helper cell differentiation, and inflammatory responses, making CRLF2 a significant target in immunology research. Aberrant CRLF2 expression has also drawn attention in hematological malignancy studies, where its overexpression is associated with certain B-cell acute lymphoblastic leukemia subtypes.

This recombinant monoclonal antibody (clone 10A4) offers the consistency and reliability that demanding experimental workflows require. Because recombinant antibodies are produced from defined sequences rather than hybridoma-derived sources, researchers benefit from lot-to-lot reproducibility that supports longitudinal studies and ensures comparable results across experiments.

Validated for both ELISA and Western blot applications, this antibody demonstrates robust performance across multiple experimental contexts. Western blot analysis confirms detection of CRLF2 at the predicted 42 kDa molecular weight in diverse human cell lines, including Jurkat, THP-1, A-431, and SH-SY5Y lysates, providing flexibility for researchers working with lymphoid, monocytic, epithelial, or neuroblastoma models. Functional ELISA data further demonstrates strong binding activity with EC50 values in the low nanogram per milliliter range for both human and cynomolgus macaque CRLF2, supporting cross-species reactivity that proves valuable for translational research involving primate models.

The human IgG1 isotype format and affinity-purified preparation ensure minimal background interference, while the unconjugated format allows researchers to select detection systems suited to their specific protocols. This antibody serves as a reliable tool for investigating TSLP signaling, immune cell biology, and related disease mechanisms.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the hematopoietic system.

Gene References into Functions

Family-based whole genome analysis of a family with hereditary pulmonary alveolar proteinosis revealed a homozygous deletion that disrupts CSF2RA, CRLF2, and IL3RA gene in the pseudoautosomal region of the X chromosome in the affected child and one of asymptomatic siblings. PMID: 28233860
TSLP expression on the basophil membrane of patients with severe asthma was not significantly different from healthy controls. PMID: 29402810
high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of acute lymphoblastic leukemia PMID: 27391346
this study shows that CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia PMID: 27449287
data suggest that this high frequency of genetic aberrations in the context of a high CRLF2 expression could contribute to the high risk of relapse in P2RY8/CRLF2- and IGH/CRLF2-positive acute lymphoblastic leukemia. PMID: 28371317
CRLF2 overexpression is associated with childhood B-cell acute lymphoblastic leukemia. PMID: 27637012
CRLF2 gene rearrangement is associated with acute lymphoblastic leukemia. PMID: 28033648
TSLPR levels were found to be significantly higher in asthmatic than in nonasthmatic children. TSLPR expression in non-allergic asthmatic and allergic asthmatic groups was found to be significantly higher than in non-allergic nonasthmatic group PMID: 26999524
In adult B-cell acute lymphoblastic leukemia without recurrent fusion genes , high CRLF2 expression is associated with distinct clinico-biological features and an unfavourable prognosis PMID: 26754556
CD4+ T cells from atopic dermatitis patients directly interacted with TSLP to produce a higher amount of IL-4 than those from normal subjects, and this action was attenuated with anti-TSLPR antibody PMID: 26288354
The levels of mRNA for TSLP and TSLPR were significantly elevated in parotid gland tissues from the KD group as compared to the control group. PMID: 25676453
Differences exist in the genetic profiles of Down syndrome-associated acute lymphoblastic leukemia patients in Japan and in Western countries, and that P2RY8-CRLF2 and EBF1 deletions may cooperate in leukemogenesis in a subset of Japanese DS-ALL patients. PMID: 25044358
CRLF2 overexpression (OE) was detected in 30 (18%) of 167 patients, the P2RY8-CRLF2 fusion was identified in only 3 (1.8%) of 167 patients, all of which demonstrated CRLF2 OE. PMID: 24935070
we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the transmembrane domain closer to the cytosolic domain in acute lymphoblastic leukemias PMID: 24787007
The TSLPR in blood plateltes promotes platelet activation via activating the PI3K/AKT pathway. PMID: 24356513
both IKZF1 deletions and IGH@-CRLF2 are associated with an increased risk of treatment failure in adult acute lymphoblastic leukemia PMID: 24018820
Data indicate that CD66c is frequently expressed in CRLF2-positive as well as hypodiploid cases. PMID: 24231528
Higher cumulative incidence of relapse was found for BCR-ABL1-like and IKZF1-deleted, but not CRLF2-high, cases relative to remaining BCP-ALL cases. PMID: 23974192
IKZF1 deletions and CRLF2-high expression predicted poor outcomes in patients with HR-ALL but not in patients with SR-ALL in our Japanese cohort PMID: 23804397
Results show no clinical or laboratory difference between those with high and low crlf2 expression PMID: 23145900
P2RY8-CRLF2-positive clones do not have the necessary proliferative or selective advantage to evolve into a disease-relevant relapse clone. PMID: 23091296
Neither CRLF2 nor JAK2 were predictors for worse prognosis in children with Down's syndrome and acute lymphoblastic leukemia. PMID: 22441210
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. PMID: 22484421
CRLF2-overexpressing B-cell acute lymphoblastic leukemias have a gain-of-function CRLF2 F232C mutation or activating mutations in JAK2. PMID: 22915648
CRLF2-deregulation and IGH locus translocations represent distinct subtypes of adolescent and adult acute lymphoblastic leukemia. PMID: 22851563
This review sums up diverse mechanisms that mediate TSLP/TSLP receptor-signalling network in chronic airway diseases. PMID: 22168549
CRLF2 overexpression is associated with acute lymphoblastic leukemia. PMID: 22297722
High CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, acute lymphoblastic leukemia. PMID: 22368272
Data indicate that overexpression of CRLF2 was not observed in adult patients with Ph-positive or T-ALL but was limited to B-ALL patients with a normal diagnostic karyotype. PMID: 21457190
review highlights the current knowledge of the incidence, prognostic significance, and biology of CRLF2-overexpressing ALL and future directions for development of targeted therapies PMID: 22150304
TSLPR expression was significantly higher in the inflammatory infiltrate and in the epithelial cells of chronic rhinosinusitis with or without nasal polyps PMID: 21978707
Integrated genomic profiling has identified potential therapeutic targets in acute lymphoblastic leukemia, including aberrant cytokine receptor signaling mediated by rearrangements and mutation of CRLF2 PMID: 21169835
Deregulated expression of CRLF2 (CRLF2-d) arises via its juxtaposition to the IGH@ enhancer or P2RY8 promoter. Among 865 BCP-ALL children treated on MRC ALL97, 52 (6%) had CRLF2-d, but it was more prevalent among Down syndrome patients (54%). PMID: 21106984
increased CRLF2 expression associates with JAK2 mutation, a combination that transforms hematopoietic cells, suggesting that mutant JAK2 and CRLF2 may cooperate to contribute to B-progenitor acute lymphoblastic leukemia formation [review] PMID: 20807819
The genotype and allele frequencies of the g.33G>C and g.19646A>G of the TSLPR gene were significantly associated in the atopic asthma patients rather than in the non-atopic asthma patients PMID: 20663412
Studies indicate that of 19 total CRLF2 breakpoints, 7 are directly at CpGs and breakpoints are much closer to CpGs than expected by random chance. PMID: 20847213
Study reports an extremely high incidence of relapse (71% +/- 19%) in non-high-risk precursor B-cell acute lymphoblastic leukemia patients with P2RY8-CRLF2 rearrangement. PMID: 20378752
Activation of CRLF2 expression, mutation of of JAK1 or JAK2, and alterations of IKZF1 cooperate to promote B-cell leukemogenesis. PMID: 20139093
The hymic stromal lymphopoietin receptor is involved in the pathogenesis of allergic asthma through the activation of human airway smooth muscle cells by t hymic stromal lymphopoietin PMID: 20483734
human TSLP receptor requires the function of JAK1 and JAK2 for STAT activation PMID: 20128689
Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia; results indicate that TSLPR activation may occur independently of a JAK2R683 mutation and that TSLPR can also be the site of a point mutation PMID: 19907440
Our data indicate that epithelial cells express TSLPR and that TSLP induces bronchial epithelial cell proliferation and increases injury repair through IL-13 production. PMID: 20236697
Induced homodimerization of receptor chimeras containing the transmembrane and cytoplasmic domains of both human and mouse TSLP receptors is not sufficient for driving cell proliferation. PMID: 20096461
Results implicate CRLF2 as an important factor in precursor B-cell acute lymphoblastic leukemia with diagnostic, prognostic, and therapeutic implications. PMID: 20018760
Results suggest that the majority of DS children with ALL may benefit from therapy blocking the CRLF2/JAK2 pathways. PMID: 19965641
Expression of TSLP receptor was upregulated on atopic DCs primed with H22-Fel d 1 through a pathway regulated by FcgammaRI-associated signaling components. PMID: 20109752
The presence of TSLP receptors is unexpectedly demonstrated on activated human CD4-positive T cells. PMID: 17513717
A causal role of CRLF2 overexpression in lymphoid transformation. PMID: 19641190
report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor acute lymphoblastic leukemia that juxtaposes the first, noncoding exon of P2RY8 with the coding region of CRLF2. PMID: 19838194

Hide All

Subcellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.

Protein Families

Type I cytokine receptor family, Type 5 subfamily

Tissue Specificity

Expressed in heart, skeletal muscle, kidney and adult and fetal liver. Primarily expressed in dendrites and monocytes. Weakly expressed in T-cells.

Database Links

HGNC: 14281

OMIM: 300357

KEGG: hsa:64109

STRING: 9606.ENSP00000370979

UniGene: Hs.287729

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA005983MA1HU
Size	US$210
	Order now
Image	The Binding Activity of Macaca fascicularis CRLF2 with Anti-CRLF2 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Macaca fascicularis CRLF2(CSB-MP5357MOVd7) at 2 μg/mL can bind Anti-CRLF2 recombinant antibody. The EC₅₀ is 2.079-2.450 ng/mL. The Binding Activity of Human CRLF2 with Anti-CRLF2 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Human CRLF2(CSB-MP005983HU-B) at 2 μg/mL on streptavidin coated plates can bind Anti-CRLF2 recombinant antibody. The EC₅₀ is 3.631-7.668 ng/mL. Western Blot Positive WB detected in: Jurkat whole cell lysate(30µg), THP-1 whole cell lysate(30µg), A-431 whole cell lysate(30µg), SH-SY5Y whole cell lysate(30µg) All lanes: CRLF2 antibody at 1:1000 Secondary Goat polyclonal to human IgG at 1/40000 dilution Predicted band size: 42 kDa Observed band size: 42 kDa Exposure time: 2min The Binding Activity of Human CRLF2 with Anti-CRLF2 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Human CRLF2(CSB-MP005983HU). at 2 μg/mL can bind Anti-CRLF2 recombinant antibody The EC₅₀ is 1.630-1.842 ng/mL.
Have Questions?	Leave a Message or Start an on-line Chat

CRLF2 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background